



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Serpin B9-IN-1

Cat. No.:	HY-33299		
CAS No.:	154235-77-5		
Molecular Formula:	C ₈ H ₅ NO ₃		
Molecular Weight:	163.13		
Target:	Biochemical Assay Reagents		
Pathway:	Others		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (613.01 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	6.1301 mL	30.6504 mL	61.3008 mL
	5 mM	1.2260 mL	6.1301 mL	12.2602 mL
	10 mM	0.6130 mL	3.0650 mL	6.1301 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Serpin B9-IN-1 (BTCA) is an inhibitor that specifically targets Serpin B9 (SB9); SB9 is a natural inhibitor of granzyme B (GrB), but may promote the metastasis of lung cancer cells into the bone marrow. SB9-overexpressing cancer cells promote proliferation and metastasis in an immune cell-dependent manner by binding to GrB. Inhibition of SB9 by Serpin B9-IN-1 significantly inhibits immunotherapy of lung cancer bone metastases in the caudal artery (CA) mouse model (LCBM)^[1].

IC₅₀ & Target

IC₅₀: Serpin B9

In Vivo

Serpin B9-IN-1 (BTCA) inhibits bone metastasis (BM) in multiple tumor metastasis models. Serpin B9-IN-1 (50 mg/kg/d; ip; 14 d) effectively reduced the survival rate and metastasis proportion of metastatic cancer cells in the mouse bone metastasis model with LLC1-BM3 injected into the tail artery (CA)^[1].

Serpin B9-IN-1 (300 µg/d; ip; 14 d) effectively delayed the average time to bone metastasis (BM) in the LLC1-BM3 cell group^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	LLC1-BM3 Bone Metastatic Mouse Model by CA injections ^[1]
Dosage:	50 mg/kg
Administration:	ip; followed after cancer cell injection, injection daily for 14 days
Result:	Reduced the survival rate and metastasis proportion of metastatic cancer cells
Animal Model:	LLC1-BM3-sr-ctrl Model in Mouse ^[1]
Dosage:	300 µg
Administration:	ip; once daily for 14 days
Result:	Delayed the mean time to occurrence of bone metastasis (BM), and lowered the burden of BM in LLC1-BM3-shSB9 cells group.

REFERENCES

[1]. Huang Y, et al. Mass Spectrometry-Based Proteomics Identifies Serpin B9 as a Key Protein in Promoting Bone Metastases in Lung Cancer. Mol Cancer Res. 2024 Apr 2;22(4):402-414.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA